ArticleCell division2026
Overexpression of ENDOD1 inhibits proliferation, migration, and invasion of colorectal cancer.
Article in Cell division, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveThis study aimed to investigate the biological function and the molecular mechanism of ENDOD1 in colorectal cancer (CRC) progression.
methodsCRC-related differentially expressed genes (DEGs) were screened by analyzing GEO datasets (GSE41657, GSE8671, GSE41328, and GSE75548). The differential expression of ENDOD1 within human CRC cell lines (HCT116, HT-29, SW620, and SW480) versus human normal colonic epithelial cells (NCM460) was validated using RT-qPCR and Western blot. ENDOD1 overexpression vector and siRNA were constructed and transfected into HT29 cells. CCK-8, flow cytometry, scratch test, and Transwell assays were performed to assess HT29 cell viability, apoptosis, and migratory and invasive abilities. The regulatory role of ENDOD1 in tumor growth in vivo was investigated using a xenograft mouse model. Moreover, a Western blot was performed to determine Wnt/β-catenin signaling activation.
resultsENDOD1 was down-regulated in CRC tissues of GSE41657, GSE8671, GSE41328, and GSE75548 datasets, as well as in CRC cell lines. ENDOD1 overexpression promoted HT29 cell apoptosis and suppressed cell viability, migration, and invasion; ENDOD1 downregulation suppressed HT29 cell apoptosis and enhanced cell viability, migration, and invasion. In vivo, ENDOD1 overexpression inhibited tumor growth, suppressed Ki67 expression, and promoted apoptosis in transplanted tumors in mice. Moreover, EMDOD1 overexpression was blocked, while ENDOD1 inhibition promoted the activation of the Wnt/β-catenin pathway. Pharmacological activation of the Wnt/β‑catenin pathway partially attenuated ENDOD1-mediated suppression in CRC cells.
conclusionENDOD1 expression level is decreased in CRC, and overexpression of ENDOD1 induces apoptosis, represses cell proliferation, migratory and invasive ability, and inhibits the Wnt/β-catenin signaling activation within CRC cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.